Royalty Pharma plc
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
2,688.58 |
2,962.84 |
3,166.42 |
3,515.80 |
4,437.00 |
4,593.00 |
| Przychód Δ r/r |
0.00% |
10.20% |
6.87% |
11.03% |
26.20% |
3.52% |
| Przychód (min) |
2,620.06 |
2,932.92 |
3,020.82 |
3,515.77 |
4,323.92 |
4,475.94 |
| Przychód (max) |
2,698.26 |
2,982.80 |
3,401.56 |
3,515.82 |
4,581.88 |
4,742.98 |
| EBITDA (średnia) |
1,729.07 |
1,905.45 |
2,036.37 |
2,261.07 |
2,853.51 |
2,953.84 |
| EBIT (średnia) |
1,626.23 |
1,792.12 |
1,915.25 |
2,126.58 |
2,683.79 |
2,778.15 |
| EBIT % |
60.49% |
60.49% |
60.49% |
60.49% |
60.49% |
60.49% |
| Zysk netto (średni) |
2,396.95 |
2,603.79 |
3,153.06 |
3,339.22 |
4,866.28 |
5,026.32 |
| Zysk netto % |
89.15% |
87.88% |
99.58% |
94.98% |
109.68% |
109.43% |
| EPS (średnia) |
4.05 |
4.39 |
5.02 |
5.63 |
8.21 |
8.48 |
| Liczba analityków (Przychody) |
5 |
3 |
5 |
5 |
1 |
2 |
| Liczba analityków (EPS) |
4 |
5 |
5 |
2 |
1 |
1 |
| symbol |
RPRX |
RPRX |
RPRX |
RPRX |
RPRX |
RPRX |